Tissue Regenix Group PLC Directorate Change (5177H)
August 01 2019 - 2:02AM
UK Regulatory
TIDMTRX
RNS Number : 5177H
Tissue Regenix Group PLC
01 August 2019
Tissue Regenix Group plc
Directorate Change
Leeds, 1 August 2019 - Tissue Regenix Group (AIM:TRX) ("Tissue
Regenix" or "The Group") the regenerative medical devices company
announces that Chief Executive Officer (CEO), Steve Couldwell, has
informed the Board that due to a recurrence of his illness, he has
decided to resign his position with immediate effect in order to
concentrate on his recovery.
John Samuel, will resume the position of Executive Chairman
until a full time CEO appointment is made. Gareth Jones, Chief
Operating Officer will take up the position of interim- CEO.
Mike Barker, who has been with the Group since January will
continue to support the Executive team as interim Finance
Director.
Steve Couldwell, CEO, Tissue Regenix Group commented: "It has
been my great privilege and honour to lead Tissue Regenix for two
years in the position of CEO. I truly believe in the strength of
our technologies, our product portfolio and market strategy. The
Company is at such an exciting point of commercial and operational
inflection and I remain committed to being available as an adviser
and mentor wherever possible."
Executive Chairman, John Samuel, commented: "The Board and I
regret the news of Steve's resignation and would like to thank him
for his inspirational leadership over the last two years.
With the support of Gareth and Mike, we continue to be well
positioned with an experienced Executive team."
For more Information:
Tissue Regenix Group plc Tel: 0330 430 3073 /
Caitlin Pearson Head of Communications 07920272 441
--------------------------------------------- ---------------------
Stifel Nicolaus Europe Limited (Nominated Tel: 0207 710 7600
Adviser and Broker)
Jonathan Senior / Alex Price / Ben Maddison
--------------------------------------------- ---------------------
FTI Consulting Tel: 0203 727 1000
Brett Pollard / Victoria Foster Mitchell
/ Mary Whittow
============================================= =====================
About Tissue Regenix
Tissue Regenix is a leading medical devices company in the field
of regenerative medicine. Tissue Regenix was formed in 2006 when it
was spun-out from the University of Leeds, UK. The company's
patented decellularisation ('dCELL(R) ') technology removes DNA and
other cellular material from animal and human soft tissue leaving
an acellular tissue scaffold which is not rejected by the patient's
body and can then be used to repair diseased or worn out body
parts. Current applications address many critical clinical needs
such as sports medicine, heart valve replacement and wound
care.
In November 2012 Tissue Regenix Group plc set up a subsidiary
company in the United States - 'Tissue Regenix Wound Care Inc.',
January 2016 saw the establishment of joint venture GBM-V, a multi-
tissue bank based in Rostock, Germany.
In August 2017 Tissue Regenix acquired CellRight Technologies(R)
, a biotech company that specializes in regenerative medicine and
is dedicated to the development of innovative osteoinductive and
wound care scaffolds that enhance healing opportunities of defects
created by trauma and disease. CellRight's human osteobiologics may
be used in spine, trauma, general orthopedic, foot & ankle,
dental, and sports medicine surgical procedures.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
BOAUGUBGRUPBUAG
(END) Dow Jones Newswires
August 01, 2019 02:02 ET (06:02 GMT)
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Sep 2024 to Oct 2024
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Oct 2023 to Oct 2024